Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | KIT positive |
| Therapy | Imatinib |
| Indication/Tumor Type | germ cell cancer |
| Response Type | no benefit |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| KIT positive | germ cell cancer | no benefit | Imatinib | Phase II | Actionable | In a small Phase II study, 6 patients with KIT-positive refractory germ cell tumors treated with Gleevec (imatinib) experienced no significant antitumor activity (PMID: 16462496). | 16462496 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (16462496) | Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT. | Full reference... |